RNATICS
Our teams
RNA THERAPY - TARGETED
RNATICS develops targeted nucleic acid therapies against disease-causing RNAs in macrophages. With our delivery technology the underlying disease biology of macrophage-driven lung diseases can be addressed beyond currently available approaches. The lead candidate RCS-21 is being developed to address exacerbating IPF patients to improve the outcome of acute exacerbations and avoid future exacerbations. It is currently in phase I clinical testing, and we expect the read-out of the trial towards the end of the year.
Founded 17/08/2021
Vision of RNATICS:
"With our targeted RNA therapies, we’re focused on bringing novel treatment options to patients in need with debilitating lung diseases leveraging the academic research of our scientific founder of more than a decade."
The team of RNATICS:
- Dr. Johannes Schmidt, CEO - LinkedIn profile
- Dr. Thomas Frischmuth, CTO - LinkedIn profile
- Prof. Dr. Dr. Stefan Engelhardt, CSO
- Prof. Dr. Klaus Rabe, CMO
- Christina Beck, Project Scientist - LinkedIn profile
- Dr. Sabrina Spiller, Project Scientist - LinkedIn profile